Teva Pharmaceuticals, Inc. is the U.S. operating entity of Teva Pharmaceutical Industries Ltd. (NYSE/TASE: TEVA), the Israeli group founded in 1901 and headquartered at 124 Dvora HaNevi'a St., Tel Aviv. Teva is publicly traded and independently owned; its 2024 SEC annual report shows revenue of about $16.5 billion and the company reports roughly 30,000–34,000 employees worldwide. Court filings in the Array case identify Teva Pharmaceutical Industries Ltd. as the affiliated parent.
Teva is one of the world's largest generic-drug manufacturers, selling hundreds of generic prescription products and reporting through three segments: United States, Europe, and International Markets. Its branded/specialty portfolio includes AUSTEDO (deutetrabenazine), AJOVY (fremanezumab), UZEDY (risperidone) and COPAXONE (glatiramer acetate); it also markets biosimilars (e.g., Truxima, Selarsdi), supplies active pharmaceutical ingredients and contract manufacturing through its TAPI business (which it has been restructuring after a failed divestiture attempt), and distributes third-party medicines via its Anda unit.
The tracked litigation posture is that of an operating company defending: 0 plaintiff cases and 3 defendant cases, all Hatch-Waxman ANDA infringement actions under 35 U.S.C. § 271(e), in the District of Delaware and the District of New Jersey — not the Eastern District of Texas or other plaintiff-heavy venues. That is the standard pattern for a generic manufacturer sued by brand owners after filing an ANDA; in the Array matter Teva answered and counterclaimed for invalidity.
The most prominent tracked cases are Array BioPharma, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 1:23-cv-00625, filed June 8, 2023), in which Pfizer-owned Array asserts crystallized-binimetinib patents (U.S. 9,562,016; 9,598,376; 9,980,944) against Teva's binimetinib ANDA and which is related to Array's parallel Alembic/Sandoz suit, and Jazz Pharmaceuticals Ireland Ltd. v. Teva Pharmaceuticals, Inc. (D.N.J., filed March 21, 2023), an oxybate (Xywav/Xyrem) case asserting U.S. 10,195,168 after Teva's February 2023 ANDA notice. The two Jazz entries appear to be duplicate records of the same New Jersey suit; litigation databases list it as terminated in December 2023.